Evidence map›Paper›PMID 41993566›Full record

ArticlebioRxiv : the preprint server for biology2026

Optical Spectral Fingerprinting Enables Sensitive Detection of Anthracycline Chemotherapeutics in Synthetic Clinical Biofluids.

Atara R Israel, Yunjung Kim, Adnan Arnaout, Myesha Thahsin, Yumna Ahmed, Zachary Cohen, Amelia Ryan, Syeda Rahman, Mijin Kim, Ryan M Williams

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Atara R IsraelDepartment of Biomedical Engineering, The City College of New York, New York, NY, USA.
Yunjung KimSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.
Adnan ArnaoutDepartment of Biomedical Engineering, The City College of New York, New York, NY, USA.
Myesha ThahsinDepartment of Biomedical Engineering, The City College of New York, New York, NY, USA.
Yumna AhmedDepartment of Biomedical Engineering, The City College of New York, New York, NY, USA.
Zachary CohenDepartment of Biomedical Engineering, The City College of New York, New York, NY, USA.
Amelia RyanDepartment of Biomedical Engineering, The City College of New York, New York, NY, USA.
Syeda RahmanDepartment of Biomedical Engineering, The City College of New York, New York, NY, USA.
Mijin KimSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.
Ryan M WilliamsDepartment of Biomedical Engineering, The City College of New York, New York, NY, USA.ORCID 0000-0002-2381-8732

Funding

Research Center in Minority Institutions (RCMI) at City CollegeU54MD017979 · NIMHD · CITY COLLEGE OF NEW YORK · PI M. Felice Marina GHILARDI · 2024 to 2026
$15.9M
G-RISE: Graduate Research Initiative for Student Advancement at The City College of New YorkT32GM136499 · NIGMS · CITY COLLEGE OF NEW YORK · PI RUTH E. STARK · 2020 to 2026
$4.9M
Integrating Real-Time Multi-System Cytokine Signaling in Chronic DiseaseR35GM142833 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI WILLIAMS, RYAN MARTIN · 2021 to 2025
$2.4M
Machine Perception Nanosensor Array Platform to Capture Whole Disease Fingerprints of Early Stage Pancreatic CancerR00EB033580 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI Mijin Kim · 2024 to 2026
$692k
NIBIB NIH HHS R00 EB033580NIGMS NIH HHS R35 GM142833NIGMS NIH HHS T32 GM136499NIMHD NIH HHS U54 MD017979
6 · The paper itself

Abstract

Anthracycline chemotherapeutics are commonly used as frontline treatments for a wide array of cancers. However, their administration to patients results in substantial side effects, primarily cardiotoxicity, as well as myelosuppression and gastrointestinal toxicity. Current clinical management of such side effects is solely based on a lifetime dosage limit, which inhibits their anti-tumor efficacy. Many individualized factors, including age, family history of cardiovascular disease, treatment regimen, and other co-morbidities influence drug pharmacology. Despite this heterogeneity, there is no method for determining actual organ or tumor exposure to the treatment in an individual. Here, we developed an optical nanosensor array for four anthracyclines-doxorubicin, daunorubicin, epirubicin, and idarubicin. We used single-walled carbon nanotubes as the signal transducer due to their tunable near-infrared fluorescence. We screened twelve distinct ssDNA sequences paired with seven SWCNT (

Indexed as

cardiotoxicityDoxorubicinmachine learningnear-infrared (NIR) fluorescencesingle-walled carbon nanotubesSWCNT

Identifiers

PMID41993566
PMCPMC13081973

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.